These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37055256)

  • 1. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis.
    Song YC; Liu SJ; Lee HJ; Liao HC; Liu CT; Wu MY; Yen HR
    J Microbiol Immunol Infect; 2023 Aug; 56(4):705-717. PubMed ID: 37055256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens.
    Ho CL; Yen LC; Huang HW; Lu CC; Hung YJ; Liao CL; Hung CM; Chiu KC
    Front Immunol; 2024; 15():1340645. PubMed ID: 38533494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
    Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens.
    Culebras E; Martínez M; Novella C; León JM; Marcos E; Delgado-Iribarren A; Ríos E
    Front Cell Infect Microbiol; 2024; 14():1370859. PubMed ID: 38572317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays.
    Kuo HC; Kuo KC; Du PX; Keskin BB; Su WY; Ho TS; Tsai PS; Pau CH; Shih HC; Huang YH; Weng KP; Syu GD
    Mol Cell Proteomics; 2023 Apr; 22(4):100507. PubMed ID: 36787877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
    Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
    J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity.
    Erra L; Uriarte I; Colado A; Paolini MV; Seminario G; Fernández JB; Tau L; Bernatowiez J; Moreira I; Vishnopolska S; Rumbo M; Cassarino C; Vijoditz G; López AL; Curciarello R; Rodríguez D; Rizzo G; Ferreyra M; Ferreyra Mufarregue LR; Badano MN; Pérez Millán MI; Quiroga MF; Baré P; Ibañez I; Pozner R; Borge M; Docena G; Bezrodnik L; Almejun MB
    J Clin Immunol; 2023 Feb; 43(2):271-285. PubMed ID: 36251205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Estephan L; Lin YC; Lin YT; Chen YH; Pan SC; Hsieh SM; Torkehagen PF; Weng YJ; Cheng HY; Estrada JA; Waits A; Chen C; Lien CE
    Vaccine; 2023 May; 41(23):3497-3505. PubMed ID: 37080829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.
    Cervantes-Torres J; Cabello-Gutiérrez C; Ayón-Núñez DA; Soldevila G; Olguin-Alor R; Diaz G; Acero G; Segura-Velázquez R; Huerta L; Gracia-Mora I; Cobos L; Pérez-Tapia M; Almagro JC; Suárez-Güemes F; Bobes RJ; Fragoso G; Sciutto E; Laclette JP
    Appl Microbiol Biotechnol; 2024 Jan; 108(1):179. PubMed ID: 38280035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing humoral immunity and CD4
    Shen CF; Fu YC; Ho TS; Chen PL; Lee NY; Tsai BY; Tsai PJ; Ko WC; Liu CC; Cheng CM; Shieh CC
    Clin Immunol; 2023 Jun; 251():109342. PubMed ID: 37100338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort.
    Huang CF; Jang TY; Wu PH; Kuo MC; Yeh ML; Wang CW; Liang PC; Wei YJ; Hsu PY; Huang CI; Hsieh MY; Lin YH; Hsiao HH; Hsu CM; Huang CT; Lee CY; Chen YH; Chen TC; Lin KD; Wang SH; Wang SF; Huang JF; Dai CY; Chuang WL; Yu ML
    Virol J; 2023 Jun; 20(1):112. PubMed ID: 37268999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood.
    Govindaraj S; Cheedarla N; Cheedarla S; Irby LS; Neish AS; Roback JD; Smith AK; Velu V
    Front Immunol; 2023; 14():1211558. PubMed ID: 37465682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.